Targeting central pathway of Glucose‐Dependent Insulinotropic Polypeptide, Glucagon and Glucagon‐like Peptide‐1 for metabolic regulation in obesity and type 2 diabetes
Diabetes, Obesity and Metabolism · 2025
DOI: 10.1111/dom.16146 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Zhimin Xu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Shanghai Pudong Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Obesity, Gastric Inhibitory Polypeptide, Glucagon-Like Peptide 1. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 155 Literaturangaben. Gefördert von: Project of Key Medical Discipline of Pudong Hospital of Fudan University, Pudong New Area Clinical Characteristic Discipline Project, Outstanding Leaders Training Program of Pudong Health Bureau of Shanghai.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Obesity and type 2 diabetes are significant public health challenges that greatly impact global well‐being. The development of effective therapeutic strategies has become more and more concentrated on the central nervous system and metabolic regulation. The primary pharmaceutical interventions for the treatment of obesity and uncontrolled hyperglycemia are now generally considered to be incretin‐based anti‐diabetic treatments, particularly glucagon‐like peptide‐1 and glucose‐dependent insulinotropic polypeptide receptor agonists. This is a result of their substantial influence on the central nervous system and the consequent effects on energy balance and glucose regulation. It is increasingly crucial to understand the neural pathways of these pharmaceuticals. The purpose of this review is to compile and present the most recent central pathways regarding glucagon‐like peptide‐1, glucose‐dependent insulinotropic polypeptide and glucagon receptors, with a particular emphasis on central metabolic regulation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, Shanghai Pudong Hospital, Fudan University, Shanghai, China.
- Fudan Zhangjiang Institute, Fudan University, Shanghai, China.
- Shanghai Key Laboratory of Vascular Lesions Regulation and Remodeling, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Shanghai, China.
ORCID-Profile: Ligang Zhou
Förderung
- Project of Key Medical Discipline of Pudong Hospital of Fudan University
- Pudong New Area Clinical Characteristic Discipline Project
- Outstanding Leaders Training Program of Pudong Health Bureau of Shanghai
- Fudan Zhangjiang Clinical Medicine Innovation Fund Project
- Fudan Good Practice Program of Teaching and Learning
- Integrative Medicine special fund of Shanghai Municipal Health Planning Committee
- Shanghai Natural Science Foundation
- Special Department Fund of the Pudong New Area Health Planning Commission
Zitieren
APA
Xu, Z., Wen, S., Dong, M., & Zhou, L. (2025). Targeting central pathway of Glucose‐Dependent Insulinotropic Polypeptide, Glucagon and Glucagon‐like Peptide‐1 for metabolic regulation in obesity and type 2 diabetes. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.16146
Vancouver
Xu Z, Wen S, Dong M, Zhou L. Targeting central pathway of Glucose‐Dependent Insulinotropic Polypeptide, Glucagon and Glucagon‐like Peptide‐1 for metabolic regulation in obesity and type 2 diabetes. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.16146
BibTeX
@article{Xu2025,
author = {Xu, Zhimin and Wen, Song and Dong, Meiyuan and Zhou, Ligang},
title = {Targeting central pathway of Glucose‐Dependent Insulinotropic Polypeptide, Glucagon and Glucagon‐like Peptide‐1 for metabolic regulation in obesity and type 2 diabetes},
journal = {Diabetes, Obesity and Metabolism},
year = {2025},
doi = {10.1111/dom.16146}
}
EUVIMED